Brokerages Set Capricor Therapeutics, Inc. (NASDAQ:CAPR) Price Target at $48.36

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been assigned an average rating of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $48.3636.

CAPR has been the subject of a number of analyst reports. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the company an “overweight” rating in a research report on Friday, March 13th. B. Riley Financial lifted their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Piper Sandler reissued an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Roth Mkm reissued a “buy” rating and issued a $38.00 price objective on shares of Capricor Therapeutics in a research report on Friday, May 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 13th.

Capricor Therapeutics Trading Down 2.6%

Capricor Therapeutics stock opened at $25.33 on Thursday. The company has a market cap of $1.47 billion, a P/E ratio of -10.92 and a beta of 0.39. Capricor Therapeutics has a 1-year low of $4.30 and a 1-year high of $40.37. The company has a fifty day simple moving average of $31.07 and a 200 day simple moving average of $27.15.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, equities research analysts forecast that Capricor Therapeutics will post -0.75 EPS for the current year.

Insider Transactions at Capricor Therapeutics

In other news, Director Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total transaction of $753,250.00. Following the completion of the transaction, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at approximately $247,758.99. This trade represents a 75.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 172,529 shares of company stock valued at $5,302,440. Insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Glenmede Trust Co. NA lifted its stake in shares of Capricor Therapeutics by 13.2% during the 1st quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock worth $1,104,000 after buying an additional 4,240 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Capricor Therapeutics by 672.0% during the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after buying an additional 361,664 shares during the last quarter. Stempoint Capital LP lifted its stake in shares of Capricor Therapeutics by 110.6% during the 1st quarter. Stempoint Capital LP now owns 37,592 shares of the biotechnology company’s stock worth $1,143,000 after buying an additional 19,739 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Capricor Therapeutics during the 1st quarter worth about $687,000. Finally, Ally Bridge Group NY LLC acquired a new stake in shares of Capricor Therapeutics during the 1st quarter worth about $3,463,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.